GlassScriptPhysician profile
Yogendra Prasad
NPI 1366447286
$4,753.04
in general payments reported to CMS, 2019-2025
29 companies · $805 in 2025
The $805 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $38.35 · 2021: $995 · 2022: $688 · 2023: $1,043 · 2024: $809 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,656.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,275.11 | 2019-2025 | |
| Pfizer INC. | $758.80 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $734.75 | 2019-2025 | Lifevest |
| Abbott Laboratories | $328.02 | 2021-2023 | Cardiomems |
| Merck Sharp & Dohme LLC | $296.57 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.89 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $186.90 | 2019-2021 | |
| Heartflow, INC. | $151.36 | 2021-2024 | |
| Edwards Lifesciences Corporation | $105.34 | 2021-2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $88.44 | 2019-2023 | Repatha |
| Novo Nordisk INC | $83.95 | 2024-2025 | Wegovy, Ozempic |
| Regeneron Healthcare Solutions, INC. | $70.42 | 2023-2024 | Evkeeza |
| Inspire Medical Systems, INC. | $50.15 | 2025 | Inspire |
| Astellas Pharma US INC | $48.83 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $42.87 | 2019-2023 | Andexxa, Brilinta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $35.23 | 2022-2024 | Watchman Access System |
| Esperion Therapeutics, INC. | $32.79 | 2021 | |
| Cvrx, INC. | $28.33 | 2023-2024 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $26.47 | 2023 | Eliquis, Camzyos |
| Atricure, INC. | $24.58 | 2024 | |
| Acist Medical Systems, INC. | $24.01 | 2022 | |
| Coloplast Corp | $22.68 | 2019 | |
| Cardiva Medical, INC. | $20.63 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Bayer Healthcare Pharmaceuticals INC. | $19.13 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $17.92 | 2023 | Arcalyst |
| Preventice Services, LLC | $16.17 | 2021 | |
| Zoll Circulation INC | $14.65 | 2023 | Catheter, Downstream Cartridge, Therox Ds2 Console |
| Lilly USA, LLC | $14.53 | 2020 | |
| Lantheus Medical Imaging, INC. | $14.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yogendra Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.